| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03923361 Details | 2019-12-18 Interventional | 2/3 | 0 | Propofol Depressive Diso… Treatment Resis… | Change in study design based on phase 1 data collection; patient burden was not feasible - | |||
| NCT03269318 Details | 2019-12-18 Interventional | 4 | 2 | Montelukast Salmeterol Xina… Theophylline Asthma | Change to Primary Endpoint resulted in development of new protocol - | |||
| NCT01445340 NCT00477698 Details | 2019-12-17 Interventional | 1 | 6 | Romidepsin Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Cutaneous T-Cel… Neoplasms | - - | |||
| NCT01441128 Details | 2019-12-17 Interventional | 1 | 20 | Crizotinib Dacomitinib Carcinoma Carcinoma, Larg… Carcinoma, Non-… Carcinoma, Squa… Lung Neoplasms Adenocarcinoma Carcinoma, Non-… | - - | |||
| NCT01336985 Details | 2019-12-17 Interventional | 1 | 5 | Irinotecan Colorectal Neop… Melanoma Neoplasm Metast… Neoplasms Neoplasm Metast… | - - | |||
| NCT01122914 Details | 2019-12-17 Interventional | 1 | 1 | Interleukin 1 R… Dermatitis Dermatitis, Ato… Eczema Allergic Diseas… Anakinra Atopic Dermatit… Kineret | - - | |||
| NCT00973804 Details | 2019-12-17 Interventional | 1 | 4 | Sirolimus Tacrolimus Hodgkin Disease Leukemia Lymphoma Lymphoma, Non-H… Multiple Myelom… Hodgkins Lympho… MDS Non-Hodgkins Ly… | - - | |||
| NCT00754221 Details | 2019-12-17 Interventional | 3 | 390 | Reboxetine Fibromyalgia Myofascial Pain… | This study has been terminated early as the esreboxetine development program is being
discontinued. There are no safety or efficacy concerns. - | |||
| NCT00688805 Details | 2019-12-17 Interventional | 1 | 40 | Propranolol Cocaine-Related… Cocaine Depende… | - - | |||
| NCT00428272 NCT01445093 Details | 2019-12-17 Interventional | 1 | 30 | Antibodies, Mon… Interferon-gamm… Interferons Lexatumumab Neuroblastoma Osteosarcoma Rhabdomyosarcom… Sarcoma Sarcoma, Ewing Ewing's Sarcoma | - - | |||
| NCT00327080 Details | 2019-12-17 Interventional | 1 | 20 | Acetylcholine Hypertension Hypertension, P… HIV | - - | |||
| NCT00334685 Details | 2019-12-16 Interventional | 2 | 136 | Pregabalin Reboxetine Pain | The Data Monitoring Committee terminated the study on the basis of futility (insufficient
clinical response). - | |||
| NCT00022971 NCT00029367 Details | 2019-12-16 Interventional | 1 | 35 | Rituximab Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, Large… Lymphoma, Mantl… Chronic Lymphoc… Diffuse Large B… Follicular Lymp… Mantle Cell Lym… Small Lymphocyt… | - - | |||
| NCT02806960 Details | 2019-12-13 Interventional | 1 | 12 | Glucagon Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… | Drug delivery was below target dose due to partial obstruction by aggregated particles. The study drug was discovered to be delivering a potential sub-target dosing to some participants, due to partial obstruction of the delivery device by aggregation of particles. The study was terminated early with no safety concern for participants. | |||
| NCT00607256 Details | 2019-12-13 Interventional | 3 | 500 | Reboxetine Fibromyalgia Myofascial Pain… | - - | |||
| NCT00028652 Details | 2019-12-13 Interventional | 1 | - | Interleukin-12 Neoplasm Metast… Metastatic Canc… | - - | |||
| NCT02423083 Details | 2019-12-12 Interventional | 1 | 2 | Guanabenz Multiple Sclero… Multiple Sclero… Sclerosis | - - | |||
| NCT00287495 NCT00304122 Details | 2019-12-12 Interventional | 1 | 10 | Sorafenib Sarcoma Sarcoma, Kaposi HHV-8 KSHV Kaposi's Sarcom… | - - | |||
| NCT00094978 NCT00098644 Details | 2019-12-12 Interventional | 1 | 23 | Alvocidib Romidepsin Carcinoma Carcinoma, Non-… Carcinoma, Smal… Esophageal Neop… Mesothelioma Mesothelioma, M… | - - | |||
| NCT03371381 2016-002543-41 Details | 2019-12-11 Interventional | 1/2 | 12 | Nivolumab Adenocarcinoma Adenocarcinoma … | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical
benefit observed in the Phase 1b portion of the study Sponsor did not proceed to Randomized phase 2 of study or enroll additional participants in phase 1b as study was stopped early, that resulted in limited evaluation of planned participant-related outcomes, PK, immunogenicity and biomarker analyses. |